Cost–effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis
- 1 March 2017
- journal article
- research article
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 6 (2) , 97-108
Abstract
Aim:To compare the cost–effectiveness of different disease-modifying therapies’ strategies for treatment of relapsing-remitting multiple sclerosis.Methods:A Markov model was developed to assess the cost–effectiveness and incremental cost–effectiveness ratios for different strategies of using disease-modifying therapies from a US third-party payer perspective. All costs were converted to 2014 US$.Results:Over 20 years, the total costs per patient were estimated at US$161,136.60 for Strategy 1 (symptom management [SM] alone), US$551,650.66 for Strategy 2 (SM and IFN-β-1a), US$703,463.60 for Strategy 3 (SM and natalizumab) and US$670,985.24 for Strategy 4 (SM and alemtuzumab). The accumulated quality-adjusted life years were 10.49, 10.66, 10.69 and 10.71 for each of the four Strategies 1–4, respectively. The resulting incremental cost–effectiveness ratios were 2,297,141.53 comparing Strategy 2 to Strategy 1, and -1,623,918.00 comparing Strategy 4 to Strategy 3.Conclusion:Strategy 1 was the cost-effective strategy for treatment of relapsing-remitting multiple sclerosis when compared with other strategies.Keywords
This publication has 41 references indexed in Scilit:
- Current and emerging therapies in multiple sclerosis: a systematic reviewTherapeutic Advances in Neurological Disorders, 2012
- Burden of a Multiple Sclerosis RelapseThe Patient - Patient-Centered Outcomes Research, 2012
- Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patientsJournal of the Neurological Sciences, 2011
- Cost-effectiveness of disease-modifying therapy for multiple sclerosisNeurology, 2011
- The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disabilityBrain, 2010
- Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transitionVojnosanitetski Pregled, 2009
- Willingness to Pay for a Quality-adjusted Life YearMedical Decision Making, 2000
- Guidelines for Pharmacoeconomic StudiesPharmacoEconomics, 1997
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Rating neurologic impairment in multiple sclerosisNeurology, 1983